Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN versus ITOVEBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN versus ITOVEBI.
CIPROFLOXACIN vs ITOVEBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, preventing bacterial DNA replication, transcription, and repair.
ITOVEBI is a monoclonal antibody that inhibits the interaction of programmed cell death protein 1 (PD-1) with its ligands PD-L1 and PD-L2, thereby enhancing T-cell-mediated antitumor immune responses.
400 mg IV every 12 hours or 500 mg orally every 12 hours for uncomplicated infections; 400 mg IV every 8 hours or 750 mg orally every 12 hours for severe/complicated infections.
12.5 mg orally once daily
None Documented
None Documented
4 hours (3-5 hours) in normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 20-50 mL/min) and 12-24 hours in severe impairment (CrCl <20 mL/min)
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCiprofloxacin + Deslanoside
"Ciprofloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCiprofloxacin + Acetyldigitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 12 hours in patients with normal renal function, allowing for once-daily dosing. Half-life is prolonged in renal impairment.
Renal (50-70% unchanged via glomerular filtration and tubular secretion); fecal (15-25% via biliary and transintestinal elimination); <1% as metabolites
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with biliary/fecal elimination contributing about 30%. The remaining 10% is metabolized.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic